We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Daily Bulletin
    • Drug Industry Daily
  • Device News
    • Trending
    • Commercial Operations
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Daily Bulletin
    • FDAnews Device Daily Bulletin Premium
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
    • eCFR and Guidances
    • White Papers
  • CenterWatch
  • About Us
    • The Company
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Supply Chain Parties Must Report Disciplinary Actions to FDA, Guidance Says

Supply Chain Parties Must Report Disciplinary Actions to FDA, Guidance Says

December 19, 2014

Starting next year, pharmaceutical wholesale distributors must submit annual reports that include detailed contact and state licensure information as well as any significant disciplinary actions taken by state or federal officials, the FDA says.

Reports of significant disciplinary actions must identify the type and final date the action was taken, as well as if it resulted in a revoked or suspended license or limited the ability of the facility to conduct drug-related business, according to draft guidance on reporting requirements for wholesale distributors and third-party logistic providers.

Third-party logistics providers must submit similar contact and licensure information as wholesale distributors, but the reporting of significant disciplinary action is voluntary, according to the guidance that implements the 2013 Drug Supply Chain Security Act.

Initial reports are due between Jan. 1, 2015, and March 31, 2015, for wholesale distributors, and from now until March 31, 2015, for third-party logistics providers. Subsequent annual reports must be filed during the first three months of each year, while disciplinary actions should be submitted within 30 days of final action.

The DSCSA establishes national standards for the licensing of supply chain entities and should make reporting easier, said Dave DeJean, vice president of the Center of Excellence at the network vendor Systech.

The first round may be difficult because it involves a new process, he said. Before the federal law, the system was mandated by regional pharmacy boards of different states, with different reporting requirements and different information, DeJean said.

The guidance follows DSCSA draft guidance last month to assist manufacturers, re-packagers, wholesale distributors and dispensers to comply with the new product tracing requirements.

Establishing a Pharma Supplier Audit Program will show you how to build a manageable and defensible supplier auditing program, helping you with these new annual reports.

Drugs Regulatory Affairs

Upcoming Events

  • 04Apr

    Optimizing Quality Control Operations with Unified Quality

  • 12Apr

    The Participant Playbook Webinar Series, Part 3 — Rethinking the Development of Participant-Centric Clinical Trial Technology

  • 20Apr

    Medical Device Enforcement: Latest Developments from the FDA, DOJ and FTC

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 26Apr

    Building the Foundation for QMS AI

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • FDA Final Order Requires PMA for Spinal Spheres

  • FDA and Lupus Research Alliance Form Drug Development Consortium

  • GSK and Scynexis Ink Antifungal Licensing Deal Drug

  • FDA Clears Bot Image’s AI Software for Prostate Cancer Screening

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing